유럽의 임상 바이오마커 시장 규모는 2023년에 71억 9,000만 달러에 달했습니다.
이 시장은 2023-2033년 7.52%의 CAGR로 확대하며, 2033년에는 148억 4,000만 달러에 달할 것으로 예측되고 있습니다. 임상 바이오마커란 질환의 조기 진단과 경과를 파악하는 데 도움이 되는 측정 가능한 생물학적 인자를 말합니다. 이러한 분자 바이오마커는 질병 연구와 치료제 개발에 새로운 길을 제시합니다.
| 주요 시장 통계 | |
|---|---|
| 예측 기간 | 2023-2033년 |
| 2023년의 평가 | 71억 9,000만 달러 |
| 2033년의 예측 | 148억 4,000만 달러 |
| CAGR | 7.52% |
유럽의 임상 바이오마커 시장은 바이오테크놀러지와 분자생물학의 발전에 힘입어 크게 성장하고 있습니다. 임상 바이오마커는 측정 가능한 생물학적 인자를 말합니다. 질병의 경과를 파악하고, 조기 진단을 돕고, 새로운 치료 표적을 발견하는 데 필수적입니다. 예후 바이오마커, 예측 바이오마커, 진단 바이오마커는 이 분야에서 사용할 수 있는 수많은 바이오마커 기반 검사 및 관련 서비스 중 일부에 불과합니다. 연구개발에 대한 투자 증가, 개인 맞춤형 치료에 대한 요구 증가, 만성질환의 유병률 증가라는 세 가지 주요 촉진요인이 이 산업을 주도하고 있습니다. 또한 유럽의 규제 환경은 새로운 바이오마커 기술의 창출과 적용을 촉진하는 방향으로 변화하고 있습니다. 이러한 수요 증가에 대응하기 위해 주요 제조업체와 서비스 프로바이더들은 제품 라인업을 확장하고 기술력 향상에 주력하고 있습니다.
유럽의 임상 바이오마커 시장에 대해 조사했으며, 시장의 개요와 국가별 동향 및 시장에 참여하는 기업의 개요 등을 제공하고 있습니다.
Introduction to Europe Clinical Biomarkers Market
The Europe clinical biomarkers market was valued at $7.19 billion in 2023 and is expected to reach $14.84 billion by 2033, growing at a CAGR of 7.52% between 2023 and 2033. Clinical biomarkers are biological factors that can be measured to help in early diagnosis and understanding of the course of a disease. These molecular biomarkers provide new avenues for the study of diseases and the development of therapeutics. The producers of numerous biomarker-based tests, such as prognostic, predictive, and diagnostic biomarkers, as well as associated services, are highlighted in this research.
| KEY MARKET STATISTICS | |
|---|---|
| Forecast Period | 2023 - 2033 |
| 2023 Evaluation | $7.19 Billion |
| 2033 Forecast | $14.84 Billion |
| CAGR | 7.52% |
Market Introduction
The market for clinical biomarkers in Europe is expanding significantly, propelled by developments in biotechnology and molecular biology. Clinical biomarkers are biological factors that may be measured. They are essential for comprehending the course of disease, helping with early diagnosis, and discovering novel targets for treatment. Prognostic, predictive, and diagnostic biomarkers are only a few of the many biomarker-based tests available in this sector, along with associated services. Three major drivers are driving the industry forward: increased investments in research and development, growing desire for personalized treatment, and rising prevalence of chronic diseases. Furthermore, Europe's regulatory environment is changing to facilitate the creation and application of novel biomarker technologies. To meet the increasing demand, top manufacturers and service providers are concentrating on broadening their product offerings and improving their technological prowess. This report delves into the current market dynamics, key players, and future trends shaping the European clinical biomarkers market.
Market Segmentation
Segmentation 1: by Country
How can this report add value to an organization?
Growth/Marketing Strategy: Product launches and upgradations accounted for the maximum number of key developments, at nearly 59% of the total developments in the clinical biomarkers market between January 2019 and December 2023. Numerous synergistic activities, fundings, and acquisitions of the market have also been tracked during the same time period.
Competitive Strategy: The Europe clinical biomarkers market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the clinical biomarkers market analyzed and profiled in the study involve established players that offer various kinds of products and services.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
Some prominent names established in this market are